“Our management team commands extensive commercial, scientific and clinical experience in amniotic allografts, including Adam McQueen who is leading this endeavor,” noted Joe Schmidt, Co-Founder and President. “Adding AmnioWrap tri-layer allograft to our portfolio is a natural expansion of our remarkable regenerative therapeutic platform. We are delivering 2021 solutions for patients in need of the newest generation of therapies to augment healing.”
McQueen, Division Vice President of Amniotic Products, added, “I’m excited to bring this revolutionary tri-layer allograft to market. Amniotic tissue has proven to be one of the more comprehensive regenerative products and is backed by extensive clinical and scientific research.” AmnioWrap™ is available in a wide variety of sizes to support treatment in multiple surgical applications, such as in plastic surgery reconstruction, orthopaedic and spine, surgical wounds, as well as chronic wounds, burn and ocular injuries or conditions.
Mark Adams, Co-Founder and Chief Executive Officer, stated, “We’re excited to add yet another exceptional technology to our product assortment to meet the needs of clinicians across a broad range of therapeutic disciplines. Placental allografts represent an important and fast-growing segment of the skin and dermal substitute market.”
“It’s important for clinicians to have multiple biotherapeutic tools at hand in order to treat patients based on their specific clinical need,” added Chief Medical Officer, Vik Sengupta, MD. “The AmnioWrap™ product line offers another option to help heal wounds and aid in limb salvage, reduce potential surgical complications, and improve quality of life for patients.”
Direct Biologics is also enrolling patients in EXIT COVID-19, its national multi-center, Phase II, placebo controlled, randomized clinical trial investigating the use of ExoFlo™ for COVID-19 associated acute respiratory distress syndrome (ARDS).